David Krempa Sells 10,223 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 10,223 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $14.73, for a total value of $150,584.79. Following the transaction, the insider now owns 612,646 shares of the company’s stock, valued at approximately $9,024,275.58. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.77, for a total transaction of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.92, for a total transaction of $253,296.84.

Eton Pharmaceuticals Stock Performance

Shares of NASDAQ ETON opened at $13.61 on Wednesday. The business has a fifty day simple moving average of $16.61 and a 200 day simple moving average of $15.04. The company has a current ratio of 1.97, a quick ratio of 1.43 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $365.02 million, a price-to-earnings ratio of -75.61 and a beta of 1.28. Eton Pharmaceuticals, Inc. has a one year low of $3.18 and a one year high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. The business had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Sell-side analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC raised its position in Eton Pharmaceuticals by 61.9% in the first quarter. Acadian Asset Management LLC now owns 402,428 shares of the company’s stock worth $5,219,000 after purchasing an additional 153,923 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Eton Pharmaceuticals by 49.1% in the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after buying an additional 31,596 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Eton Pharmaceuticals by 34.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after buying an additional 45,341 shares in the last quarter. Millennium Management LLC raised its stake in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after acquiring an additional 217,042 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Eton Pharmaceuticals during the first quarter worth $704,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective (up previously from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday, May 29th. Finally, B. Riley reaffirmed a “buy” rating and issued a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.